3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
Published 2 years ago • 158 plays • Length 4:52Download video MP4
Download video MP3
Similar videos
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
-
5:56
aphinity trial: adjuvant her2-targeted therapy in her2 bc
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani
-
10:08
evolving role of her2 targeted therapies in gastroesophageal cancers
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
31:21
novel therapeutics for breast cancer: her2 and triple negative disease; new pathways, targets
-
1:16:56
navigating the integration of trop2-targeted therapy in tnbc and hr , her2- breast cancer
-
28:57
for pharmacists: evolution of her2-targeted therapy in gastroesophageal adenocarcinoma
-
0:57
neohip: neoadjuvant her2-targeted therapy /- io with pembrolizumab
-
7:42
results from the aphinity trial of two her2 targeted agents with chemo
-
5:46
use of her2-targeted therapy in breast cancer
-
3:15
investigating targeted therapy combinations in metastatic hr breast cancer
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
0:52
rxponder 2024 - amh to determine the benefit of chemotherapy in early breast cancer.
-
3:12
advances in her2-targeted therapies for gastric cancer